InvestorsHub Logo

RVL

Followers 5
Posts 402
Boards Moderated 0
Alias Born 03/30/2012

RVL

Re: sci101 post# 21038

Saturday, 12/13/2014 7:36:06 AM

Saturday, December 13, 2014 7:36:06 AM

Post# of 30437
sci101,
Thanks for the heads up up, I like the quote:

"In total, Takeda’s ambition is to double its revenue over the next five years. “We will continue to put substantial resources behind our primary care business,” notes Hiro Fukutomi, managing director of Takeda UK. Evidence to that effect is the recent launch of two products into the UK primary care market: Vipidia (alogliptin) for diabetes and Vitaros (alprostadil cream) for erectile dysfunction."

You don't make that statement if sales are bad.
RVL
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SEEL News